Capricor Therapeutics Reports Widened Q1 Net Loss Amid Strategic Commercial Preparations
CAPR has more than doubled off its 52-week low of $4.3.
Summary
Capricor Therapeutics reported a widened net loss of -$0.59 per share for Q1 2026, with no revenue. The increased loss was primarily driven by higher research and development and administrative costs, specifically due to commercial preparations for its lead therapy, Deramiocel. This strategic spending includes manufacturing expansion and stockpiling in anticipation of a potential FDA approval, with a PDUFA target date in August 2026. The company expects its cash balance to fund operations into Q4 2027, excluding potential product sales. This update provides critical insight into the company's burn rate as it invests heavily ahead of a major regulatory decision. Traders will closely monitor the FDA decision on Deramiocel by August 22, 2026, and subsequent commercialization efforts.
At the time of this announcement, CAPR was trading at $31.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $4.30 to $40.37. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.